Total Payments
$118,706
2024 Payments
$87,509
Companies
8
Transactions
73
Medicare Patients
1,113
Medicare Billing
$307,681
Payment Breakdown by Category
Consulting$66,447 (56.0%)
Research$37,957 (32.0%)
Travel$13,374 (11.3%)
Food & Beverage$777.31 (0.7%)
Education$150.64 (0.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $66,447 | 43 | 56.0% |
| Unspecified | $37,957 | 2 | 32.0% |
| Travel and Lodging | $13,374 | 12 | 11.3% |
| Food and Beverage | $777.31 | 10 | 0.7% |
| Education | $150.64 | 6 | 0.1% |
Payments by Type
General
$80,749
71 transactions
Research
$37,957
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $80,976 | 40 | $0 (2024) |
| Novo Nordisk Inc | $15,509 | 12 | $0 (2024) |
| Mallinckrodt Enterprises LLC | $8,100 | 6 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $7,995 | 9 | $0 (2023) |
| Lilly USA, LLC | $5,948 | 1 | $0 (2024) |
| Covidien LP | $138.15 | 2 | $0 (2018) |
| Amgen Inc. | $35.90 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $87,509 | 31 | Eli Lilly and Company ($66,181) |
| 2023 | $15,595 | 21 | Eli Lilly and Company ($14,796) |
| 2022 | $4,040 | 9 | AstraZeneca Pharmaceuticals LP ($3,911) |
| 2021 | $2,529 | 2 | AstraZeneca Pharmaceuticals LP ($2,529) |
| 2020 | $778.00 | 1 | AstraZeneca Pharmaceuticals LP ($778.00) |
| 2019 | $4,067 | 4 | Mallinckrodt Enterprises LLC ($4,050) |
| 2018 | $2,838 | 4 | Mallinckrodt LLC ($2,700) |
| 2017 | $1,350 | 1 | Mallinckrodt LLC ($1,350) |
All Payment Transactions
73 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,087.50 | General |
| 11/20/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $362.50 | General |
| 10/04/2024 | Eli Lilly and Company | — | Travel and Lodging | Cash or cash equivalent | $46.00 | General |
| 10/04/2024 | Eli Lilly and Company | — | Travel and Lodging | Cash or cash equivalent | $37.52 | General |
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $37,372.00 | Research |
| Study: TIRZEPATIDE STUDY OF RENAL FUNCTION IN PEOPLE WITH OVERWEIGHT OR OBESITY AND CHRONIC KIDNEY DISEASE WITH OR WITHOUT TYPE 2 DIABETES: FOCUS ON KIDNEY HYPOXIA IN RELATION TO FATTY KIDNEY DISEASE USING MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING | ||||||
| 09/18/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $2,175.00 | General |
| 09/18/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,993.75 | General |
| 09/18/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,812.50 | General |
| 09/18/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $725.00 | General |
| 09/09/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $5,167.30 | General |
| 09/03/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $5,800.00 | General |
| 09/03/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $906.25 | General |
| 09/03/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $906.25 | General |
| 08/19/2024 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $3,637.50 | General |
| 08/15/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $358.81 | General |
| 08/14/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,268.75 | General |
| 08/14/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $181.25 | General |
| 06/24/2024 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $9,093.75 | General |
| 06/24/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $751.07 | General |
| 06/24/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $547.00 | General |
| 06/24/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $471.04 | General |
| 06/24/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $357.76 | General |
| 06/24/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $36.85 | General |
| 06/23/2024 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $485.00 | General |
| 03/15/2024 | Eli Lilly and Company | — | Travel and Lodging | Cash or cash equivalent | $69.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TIRZEPATIDE STUDY OF RENAL FUNCTION IN PEOPLE WITH OVERWEIGHT OR OBESITY AND CHRONIC KIDNEY DISEASE WITH OR WITHOUT TYPE 2 DIABETES: FOCUS ON KIDNEY HYPOXIA IN RELATION TO FATTY KIDNEY DISEASE USING MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING | Eli Lilly and Company | $37,957 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 122 | 263 | $101,407 | $39,941 |
| 2022 | 10 | 283 | 644 | $214,861 | $79,249 |
| 2021 | 9 | 278 | 609 | $218,005 | $83,515 |
| 2020 | 12 | 430 | 905 | $308,439 | $104,977 |
Total Patients
1,113
Total Services
2,421
Medicare Billing
$307,681
Procedure Codes
37
All Medicare Procedures & Services
37 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 14 | 89 | $54,290 | $23,774 | 43.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 39 | 99 | $21,483 | $8,790 | 40.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 23 | 23 | $9,706 | $2,847 | 29.3% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 11 | 13 | $7,462 | $1,982 | 26.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 16 | 18 | $5,274 | $1,427 | 27.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 19 | 21 | $3,192 | $1,121 | 35.1% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 18 | 125 | $76,250 | $33,283 | 43.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 78 | 209 | $45,353 | $15,974 | 35.2% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 17 | 39 | $19,890 | $8,655 | 43.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 35 | 35 | $14,770 | $5,178 | 35.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 55 | 95 | $14,440 | $4,977 | 34.5% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 19 | 20 | $11,480 | $3,257 | 28.4% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 25 | 51 | $14,025 | $2,756 | 19.6% |
| 90945 | Dialysis procedure including 1 evaluation | Facility | 2022 | 11 | 39 | $10,725 | $2,527 | 23.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 11 | 16 | $4,688 | $1,667 | 35.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 14 | 15 | $3,240 | $975.19 | 30.1% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2021 | 27 | 155 | $94,550 | $42,495 | 44.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 70 | 168 | $36,456 | $13,146 | 36.1% |
| 90961 | Dialysis services (2-3 physician visits per month), patient 20 years of age and older | Office | 2021 | 17 | 35 | $17,850 | $7,961 | 44.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 37 | 40 | $16,880 | $5,695 | 33.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 41 | 84 | $12,768 | $4,571 | 35.8% |
| 90935 | Hemodialysis procedure with one physician evaluation | Facility | 2021 | 34 | 71 | $19,525 | $3,962 | 20.3% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 19 | 19 | $10,906 | $2,913 | 26.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 20 | 23 | $4,968 | $1,430 | 28.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 13 | 14 | $4,102 | $1,342 | 32.7% |
About Dr. Allon Friedman, M.D
Dr. Allon Friedman, M.D is a Nephrology healthcare provider based in Indianapolis, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1639134364.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Allon Friedman, M.D has received a total of $118,706 in payments from pharmaceutical and medical device companies, with $87,509 received in 2024. These payments were reported across 73 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($66,447).
As a Medicare-enrolled provider, Friedman has provided services to 1,113 Medicare beneficiaries, totaling 2,421 services with total Medicare billing of $307,681. Data is available for 4 years (2020–2023), covering 37 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Other Specialties Nephrology, Internal Medicine
- Location Indianapolis, IN
- Active Since 04/18/2006
- Last Updated 03/12/2025
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1639134364
Products in Payments
- LOKELMA (Drug) $7,217
- INVOS (Device) $138.15
- MOUNJARO (Drug) $54.00
- TAVNEOS (Drug) $18.48
- Parsabiv (Biological) $17.42
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Indianapolis
Rajiv Agarwal, M.d, M.D
Nephrology — Payments: $1.8M
Nephrology $1.8M
Jay Wish, Md, MD
Nephrology — Payments: $612,981
Nephrology $612,981
Bruce Molitoris, M.d, M.D
Nephrology — Payments: $155,177
Nephrology $155,177
Dr. Arjun Sinha, M.d, M.D
Nephrology — Payments: $103,353
Nephrology $103,353
Sharon Moe, M.d, M.D
Nephrology — Payments: $40,018
Nephrology $40,018
Dr. James Elliott, M.d, M.D
Nephrology — Payments: $36,268
Nephrology $36,268